Print Page     Close Window     

SEC Filings

10-Q
SERES THERAPEUTICS, INC. filed this Form 10-Q on 11/08/2018
Entire Document
 

SERES THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited, in thousands, except share and per share data)

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Collaboration revenue - related party

 

$

8,684

 

 

$

23,015

 

 

$

16,721

 

 

$

29,044

 

Grant revenue

 

 

371

 

 

 

 

 

 

917

 

 

 

 

Total revenue

 

 

9,055

 

 

 

23,015

 

 

 

17,638

 

 

 

29,044

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

 

23,675

 

 

 

22,210

 

 

 

71,188

 

 

 

65,413

 

General and administrative expenses

 

 

7,591

 

 

 

8,119

 

 

 

25,063

 

 

 

25,251

 

Total operating expenses

 

 

31,266

 

 

 

30,329

 

 

 

96,251

 

 

 

90,664

 

Loss from operations

 

 

(22,211

)

 

 

(7,314

)

 

 

(78,613

)

 

 

(61,620

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

262

 

 

 

379

 

 

 

958

 

 

 

1,193

 

Total other income (expense), net

 

 

262

 

 

 

379

 

 

 

958

 

 

 

1,193

 

Net loss

 

$

(21,949

)

 

$

(6,935

)

 

$

(77,655

)

 

$

(60,427

)

Net loss per share attributable to common stockholders, basic

   and diluted

 

$

(0.54

)

 

$

(0.17

)

 

$

(1.91

)

 

$

(1.49

)

Weighted average common shares outstanding, basic and diluted

 

 

40,806,413

 

 

 

40,494,049

 

 

 

40,699,422

 

 

 

40,419,522

 

Other comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain on investments, net of tax of $0

 

$

20

 

 

$

77

 

 

$

137

 

 

$

50

 

Total other comprehensive income

 

 

20

 

 

 

77

 

 

 

137

 

 

 

50

 

Comprehensive loss

 

$

(21,929

)

 

$

(6,858

)

 

$

(77,518

)

 

$

(60,377

)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

5



© Seres Therapeutics. All Rights Reserved.